Cargando…
Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
Background: Limited previous research and guidelines on the design of economic evaluation for biosimilars have led to unresolved methodological questions on how to assess biosimilars. Objectives: We want to raise awareness of and explore methodological issues for the economic evaluation of biosimila...
Autores principales: | Moorkens, Evelien, Broux, Hannah, Huys, Isabelle, Vulto, Arnold G., Simoens, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144192/ https://www.ncbi.nlm.nih.gov/pubmed/32284827 http://dx.doi.org/10.1080/20016689.2020.1739509 |
Ejemplares similares
-
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016) -
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
por: Moorkens, Evelien, et al.
Publicado: (2019) -
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
por: Moorkens, Evelien, et al.
Publicado: (2019) -
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020) -
A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study
por: Moorkens, Evelien, et al.
Publicado: (2020)